Cd137 agonist antibodies and uses thereof
AssigneeQlsf Biotherapeutics Inc.
InventorsAaron Kurtzman, Hieu Tran, Shihao Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides isolated binding molecules that bind to and activates CD137, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
Claims27
An isolated anti-CD137 agonist antibody, or an antigen-binding portion thereof comprising a heavy chain variable region CDR3 comprising SEQ ID NO:8.
An isolated anti-CD137 agonist antibody, or an antigen-binding portion thereof comprising a heavy chain variable region CDR3 comprising SEQ ID NO:31.
An isolated monoclonal antibody or antigen binding portion thereof, comprising a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:33, 37-39 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:32, 34, 40-42.
An isolated monoclonal antibody or antigen binding portion thereof, comprising a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:43-46 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:47-50.
Dependencies are inferred from the claim text.